Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pronova BioPharma, developer and manufacturer of lipid therapies derived from nature, has initiated patient dosing in a placebo-controlled, double-blind single and multiple oral dose Phase I trial evaluating PRC-4016 as a treatment for combined dyslipidemia.
Subscribe to our email newsletter
The trial aims to evaluate the safety, tolerability and pharmacokinetics of PRC-4016 in healthy volunteers.
Pronova CEO Morten Jurs said they believe PRC-4016 has an optimal profile to set new standards in the treatment of dyslipidemia, where there is a significant medical need for approaches capable of reducing triglycerides and non-HDL-C levels in the blood while raising levels of HDL-C.